Amicus Therapeutics (NASDAQ: FOLD) Shares Surge on Study Results: U.S. Daily Market Movers

Published:

Small
cap stocks making big moves on Wednesday, August 20, 2014 (as of 4 pm EST), as
reported by Sean Mason, SmallCapPower.com 

Amicus Therapeutics (NASDAQ: FOLD)
shares jumped 20% to $5.50 on volume of more than 33.6 million shares Wednesday
after the biopharmaceutical company reported that its potential Fabry disease
treatment drug migalastat met its primary endpoints in a late-stage study.
Fabry is a rare genetic disease that causes fat to build up in the body
and causes pain, loss of hearing and cloudy eyes.

As well,
shares of NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY)
sank 35% to $0.81 on more than 3.2 million shares traded as the company said its
NVC-422 ophthalmic formulation did not meet the primary or secondary endpoints
in a Phase 2 clinical study in patients with adenoviral conjunctivitis.

Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX),
meanwhile, announced that it estimates its fiscal 2014 revenue to be in the
range of $110 million to $120 million with Adjusted EBITDA of $22 million to
$24 million, following the closing of its acquisition of Treximet. Pernix
Therapeutics stock popped 18% to $8.26 on the news.

Finally,
Highpower International, Inc. (NASDAQ: HPJ)
shares climbed 10% to $5.33 after the manufacturer of lithium and nickel-metal
hydride rechargeable batteries reported that it started shipping its advanced
compact lithium battery product developed for TIMEX smartwatchs. 

Related articles

Recent articles